Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

Rhea-AI Summary

On May 17, 2021, Nuvo Pharmaceuticals (MRVFF) held its Virtual Annual Meeting of Shareholders where all nominated directors were successfully elected. Notable votes included Daniel Chicoine receiving 91.55% support and David A. Copeland with 97.50%. The appointment of Ernst & Young LLP as auditors for the upcoming fiscal year was also approved. Miravo Healthcare, the company’s operating name, continues to expand its diversified portfolio, focusing on therapeutic areas such as pain and allergy, with operations in Canada, Ireland, and a manufacturing facility in Québec.

Positive

• All board nominees were elected with substantial support, indicating shareholder confidence.
• Appointment of Ernst & Young LLP as auditors passed, ensuring reliable financial oversight.

Negative

• None.

MISSISSAUGA, ON, May 17, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2021 Virtual Annual Meeting of Shareholders held on May 17, 2021 (the Meeting), all nominees listed in the management proxy circular dated April 9, 2021 were elected as directors of the Company.

The detailed results of the votes by proxy and virtual votes received at the Meeting are as follows:

DIRECTOR NOMINEES	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel Chicoine	2,523,485	232,767	91.55%	8.45%
David A. Copeland	2,687,459	68,793	97.50%	2.50%
Anthony E. Dobranowski	2,652,757	103,495	96.25%	3.75%
Robert Harris	2,687,624	68,628	97.51%	2.49%
John C. London	2,528,050	228,202	91.72%	8.28%
Mary Ritchie	2,692,270	63,982	97.68%	2.32%

In addition, the Company reports that the appointment of Ernst & Young LLP as the Company's auditors for the ensuing fiscal year was passed by a majority of the votes represented at the Meeting. The Company's full report of voting results on matters presented at the Meeting can be found at www.sedar.com.

About Miravo Healthcare   
Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.  The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology.  The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.  Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company's manufacturing facility is located in Varennes, Québec, Canada.  The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration.  For additional information, please visit www.miravohealthcare.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/miravo-healthcare-announces-director-election-results-of-its-annual-meeting-of-shareholders-301292844.html

SOURCE Nuvo Pharmaceuticals Inc.

FAQ

What was the outcome of the annual meeting of shareholders for MRVFF?

All nominees were elected with significant shareholder support.

Who were the directors elected at the Miravo Healthcare annual meeting?

Directors elected included Daniel Chicoine, David A. Copeland, and others.

What percentage of votes did David A. Copeland receive?

David A. Copeland received 97.50% of the votes in favor.

When was the Miravo Healthcare annual meeting held?

The annual meeting was held on May 17, 2021.

Who is the auditor for Miravo Healthcare following the shareholder meeting?

Ernst & Young LLP was appointed as the auditor for the upcoming fiscal year.